피부암 피부과 시장 : 암 유형, 치료법, 치료제 유형, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Skin Cancer Dermatology Market is projected to grow by USD 14.98 billion at a CAGR of 7.48% by 2032.

Skin cancer dermatology is moving from episodic lesion treatment to an integrated care model spanning prevention, screening, dermoscopy, molecular diagnostics, surgery, systemic therapy, survivorship, and digital follow-up. The clinical need is measurable: GLOBOCAN 2022 reported more than 330,000 new melanoma cases worldwide, while keratinocyte cancers, including basal cell carcinoma and cutaneous squamous cell carcinoma, remain substantially undercounted in many cancer registries. In the United States, the American Academy of Dermatology states that skin cancer is the most common cancer and that about 1 in 5 Americans will develop it in their lifetime.

For biopharmaceutical, diagnostic, device, and care-delivery innovators, demand is shaped by rising ultraviolet exposure risk, aging populations, organ-transplant-related immunosuppression, occupational and recreational sun exposure, and longer survival after earlier detection. Growth opportunities are strongest where dermatology, oncology, pathology, primary care, and digital health converge around evidence-based screening, biomarker-guided therapy, high-risk patient surveillance, and equitable access to specialty skin cancer care.

Transformative Shifts in the Skin Cancer Dermatology Landscape

The skin cancer dermatology landscape is being reshaped by earlier detection, broader use of dermoscopy, high-resolution imaging, total-body photography, Mohs micrographic surgery for high-risk non-melanoma skin cancers, and rapid advances in melanoma treatment. Immune checkpoint inhibitors and BRAF/MEK-targeted regimens have changed treatment expectations for advanced melanoma, while hedgehog pathway inhibitors and PD-1 therapy have expanded options for select advanced basal cell carcinoma and cutaneous squamous cell carcinoma.

At the same time, dermatology practices are adopting teledermatology, electronic referral pathways, risk-stratified surveillance, digital pathology, and multidisciplinary tumor boards to shorten time from suspicious lesion identification to definitive care. These shifts favor organizations that can demonstrate clinical benefit, real-world outcomes, safety, cost-effectiveness, and workflow compatibility across academic centers, specialty skin cancer clinics, and community dermatology settings.

Cumulative Impact of Artificial Intelligence on Skin Cancer Care

Artificial intelligence is becoming a cumulative force across lesion triage, dermoscopy image interpretation, digital pathology, patient engagement, clinical-trial operations, and post-treatment monitoring. Peer-reviewed studies have shown that AI models can match or exceed clinician-level performance in controlled image-classification tasks, but regulators and professional societies continue to emphasize prospective validation, diverse training datasets, explainability, clinician oversight, and performance assessment across different skin tones and care environments.

For treatment developers and dermatology care networks, AI is most valuable when it improves the full evidence chain: identifying high-risk patients earlier, enriching trials with appropriate candidates, supporting pathology review, detecting recurrence patterns, and monitoring treatment-related adverse events. The strongest commercial use cases will combine AI-enabled workflows with FDA-aligned software governance, bias testing, cybersecurity safeguards, privacy-by-design architecture, and interoperability with electronic health records.

Key Regional Insights Across Major Skin Cancer Dermatology Markets

In North America, high public awareness, strong biopsy and pathology capacity, Mohs surgery availability, and rapid uptake of immuno-oncology keep the United States and Canada at the forefront of skin cancer dermatology adoption. Europe benefits from organized cancer systems, national melanoma registries, guideline-led reimbursement, and established dermatology-oncology referral pathways, although access, waiting times, and reimbursement conditions vary by country.

Asia-Pacific is expanding as China, India, Japan, Australia, and South Korea invest in dermatology infrastructure, digital health, cancer screening, and oncology innovation; Australia remains a global reference point for prevention because of its high ultraviolet burden, established skin cancer clinic model, and mature sun-safety programs. Latin America shows rising demand in Brazil and Mexico, supported by private dermatology growth, urban specialty care, and increasing awareness, but constrained by uneven screening, pathology, and specialist access. The Middle East is advancing through specialty clinics, digital health investment, and medical tourism in high-income Gulf markets, while Africa presents long-term opportunities linked to awareness campaigns and urban care expansion, with underdiagnosis, limited pathology capacity, and late presentation remaining important barriers.

Key Group Insights for Strategic Market Prioritization

The G7 concentrates advanced dermatology research, oncology trials, regulatory influence, specialist infrastructure, and premium reimbursement pathways, making it central for launch sequencing, clinical evidence generation, and post-approval real-world studies in melanoma and non-melanoma skin cancer. The European Union adds harmonized medical-device rules, health data-protection requirements, and cross-border cancer initiatives that support registry development, quality standards, and structured evaluation of digital dermatology tools.

BRICS markets offer scale, expanding oncology capacity, and rising private healthcare demand, but they require localized pricing, distribution, patient navigation, and physician education because screening intensity and specialist access vary widely. ASEAN is attractive for teledermatology, private hospital networks, and hub-and-spoke specialist models, especially where dermatologist density is limited outside major cities. GCC countries are investing in specialty clinics, digital health, and preventive care as part of health-system modernization, creating opportunities for advanced diagnostics and premium care pathways. NATO markets overlap with many high-income healthcare systems and can influence cybersecurity expectations, procurement standards, clinical-data governance, and resilient medical supply chains for dermatology devices, therapeutics, and diagnostic services.

Key Country Insights in Skin Cancer Dermatology

The United States leads in skin cancer treatment innovation through high procedure volumes, strong dermatology and oncology networks, clinical-trial activity, Mohs surgery utilization, and rapid adoption of FDA-approved oncology therapies. Canada emphasizes publicly funded care, prevention, and guideline-based referral pathways, while Mexico and Brazil show growing private dermatology demand, increasing cosmetic and procedural dermatology capacity, and a need for broader screening access. The United Kingdom, Germany, France, Italy, and Spain are shaped by national health technology assessment, guideline compliance, cancer pathway targets, and pressure to prove value across diagnostics, therapeutics, and digital tools; Russia maintains specialist capacity in major urban centers but faces access variability and supply-chain constraints.

China and India provide the largest long-term patient-pool opportunities, although diagnosis rates vary by geography, specialist availability, and public awareness, and skin cancer is often less visible than other cancers in national priorities. Japan and South Korea have sophisticated hospital systems, advanced imaging adoption, strong pathology services, and digital health capacity that can support AI-enabled dermatology and precision oncology. Australia is strategically important because of its high melanoma burden, prevention expertise, nationwide sun-safety culture, and well-established skin cancer clinic model, making it a key benchmark for integrated prevention, early detection, and surveillance strategies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence packages that connect earlier diagnosis with measurable downstream outcomes, such as reduced advanced disease, fewer repeat procedures, improved survival, better quality of life, and lower total cost of care. Treatment innovators should pair pivotal trial data with real-world evidence from community dermatology, oncology, and pathology settings to satisfy clinicians, payers, regulators, and health technology assessment bodies.

Commercial strategy should include dermatology-oncology referral partnerships, physician education on high-risk lesions, patient adherence support, survivorship programs, and equitable access initiatives for underserved populations. Organizations using AI should implement prospective validation, bias monitoring across skin tones, transparent performance reporting, cybersecurity controls, data privacy safeguards, and clear clinician-in-the-loop workflows before scaling AI-enabled skin cancer dermatology solutions.

Research Methodology

This executive summary is based on triangulation of epidemiology, clinical guidelines, regulatory trends, payer dynamics, technology adoption patterns, and care-delivery evidence. Data-backed inputs include GLOBOCAN 2022 cancer estimates, American Academy of Dermatology public health statistics, cancer society guidance, peer-reviewed clinical literature, health authority communications, and regulatory principles for AI-enabled medical software and digital health technologies.

The analysis applies a market-intelligence framework combining disease burden, dermatology and pathology access, reimbursement maturity, digital readiness, treatment innovation, prevention infrastructure, and regional health-system capacity. Insights are organized to support executive decision-making across strategy, commercialization, partnerships, clinical evidence generation, regulatory planning, and skin cancer dermatology access models.

Conclusion: Building Sustainable Growth in Skin Cancer Dermatology

Skin cancer dermatology is entering a more connected era in which prevention, detection, pathology, surgery, systemic therapy, surveillance, and follow-up are increasingly managed as one continuum. The sector is supported by undeniable disease burden, continued innovation in melanoma and non-melanoma skin cancer treatment, wider use of dermoscopy and Mohs surgery, and growing digital enablement through teledermatology, imaging, pathology, and AI-assisted workflows.

Organizations that combine clinical evidence, access strategy, AI governance, multidisciplinary care design, and localized market execution will be best positioned to improve outcomes and capture sustainable growth in skin cancer dermatology while supporting earlier detection, more precise treatment, and more equitable patient care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Skin Cancer Dermatology Market, by Cancer Type

• 7.1. Basal Cell Carcinoma
• 7.2. Melanoma
• 7.3. Squamous Cell Carcinoma

8. Skin Cancer Dermatology Market, by Treatment Modality

• 8.1. Photodynamic Therapy
• 8.2. Radiotherapy
• 8.3. Surgical Procedures
  • 8.3.1. Cryosurgery
  • 8.3.2. Curettage And Electrodesiccation
  • 8.3.3. Excisional Surgery
  • 8.3.4. Mohs Surgery
• 8.4. Topical Medications

9. Skin Cancer Dermatology Market, by Therapeutic Class

• 9.1. Chemotherapy Agents
• 9.2. Immunotherapies
  • 9.2.1. Checkpoint Inhibitors
  • 9.2.2. Cytokine Therapies
  • 9.2.3. Oncolytic Viruses
• 9.3. Photodynamic Agents
• 9.4. Targeted Therapies

10. Skin Cancer Dermatology Market, by End User

• 10.1. Ambulatory Surgical Centers
• 10.2. Dermatology Clinics
• 10.3. Hospitals

11. Skin Cancer Dermatology Market, by Distribution Channel

• 11.1. Hospital Pharmacies
• 11.2. Online Pharmacies
• 11.3. Retail Pharmacies

12. Skin Cancer Dermatology Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Skin Cancer Dermatology Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Skin Cancer Dermatology Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. AbbVie Inc.
• 16.2. Almirall, S.A.
• 16.3. Amgen Inc.
• 16.4. Arcutis Biotherapeutics, Inc.
• 16.5. Bausch Health Companies Inc.
• 16.6. Bristol-Myers Squibb Company
• 16.7. DermBiont, Inc.
• 16.8. Eli Lilly and Company
• 16.9. F. Hoffmann-La Roche Ltd
• 16.10. Galderma S.A.
• 16.11. GSK plc
• 16.12. Incyte Corporation
• 16.13. Johnson & Johnson Services, Inc.
• 16.14. LEO Pharma A/S
• 16.15. Merck & Co., Inc.
• 16.16. Novartis AG
• 16.17. Pfizer Inc.
• 16.18. Regeneron Pharmaceuticals, Inc.
• 16.19. Sanofi S.A.
• 16.20. UCB S.A.